Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients (ANTISTAPH)

Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

Ex Vivo Evaluation of Immunity Activation Face to Staphylococcus Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

S. aureus is a leading cause of severe infections notably in haemodialysis patients. These patients have a high risk of S. aureus nasal carriage, with a rate of persistent carriage near 30%. These carriers are particularly at risk of S. aureus infections as we previously shown. High risk of S. aureus infections such as bacteremia occurred notably in patients with dialysis catheters. Decolonization of carriers may prevent such infections however this approach has limits. Development of an effective S. aureus vaccine is crucial. To date, past vaccines tested (phase III) failed to achieve their end points. Target of only one or few antigens, absence of cellular response induction and possibly no impact on carriage are probably the reasons of the failures.

In an attempt to minimize failure in a clinical phase, ex vivo analysis of immune response of leucocytes of haemodialysis patients face to S. aureus and the impact of antigens and adjuvants of a candidate vaccine may help.

There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.

Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.

EX VIVO measure of innate immunity : phenotype activation of different cell types from PBMCs (peripheral blood mononuclear cells) to S. aureus vaccine antigens

EX VIVO measures of innate immunity: chemokines and cytokines secretions to S. aureus vaccine antigens

EX VIVO measure of acquired immunity: measures of S. aureus antibodies titre in serum to S. aureus vaccine antigens

EX VIVO measure of innate immunity: functional capacity of neutrophils to S. aureus vaccine adjuvants

EX VIVO measure of innate immunity : phenotype activation of different cell types from PBMCs (peripheral blood mononuclear cells) to S. aureus vaccine adjuvants

EX VIVO measures of innate immunity: chemokines and cytokines secretions to S. aureus vaccine adjuvants

EX VIVO measure of acquired immunity: measures of S. aureus antibodies titre in serum to S. aureus vaccine adjuvants

Investigation of the presence of antigens of interest selected for the vaccine approach in strains of S. aureus in the nasal carriage

Inclusion Criteria: Patient starting haemodialysis for chronic hemodialysis. Patient starting haemodialysis on catheter Patient who signed the informed consent form Exclusion Criteria: Pregnant woman Patient who starts Haemodialysis for over 3 months Patient with anemia (hemoglobin <7 g / dL)